Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease

详细信息    查看全文

• 作者：Rachel Howe ; Rita M Mirakian ; Prathap Pillai…
• 关键词：Aspirin exacerbated respiratory disease ; Lysine aspirin ; Nasal polyposis ; Late onset asthma
• 刊名：World Allergy Organization Journal
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：7
• 期：1
• 全文大小：1,035 KB
• 参考文献：1. Teran, LM, Holgate, ST, Park, HS, Sampson, AP (2012) Editorial. Aspirin Exacerbated Respiratory Disease. Journal of Allergy 2012: pp. 473863 CrossRef
  2. Daffern, P, Muilenburg, D, Hugli, TE, Stevenson, DD (1999) Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 104: pp. 559-564 CrossRef
  3. Sanak, M, Levy, BD, Clish, CB, Chiang, N, Gronert, K, Mastalerz, L, Serhan, CN, Szczeklik, A (2000) Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 16: pp. 44-49 CrossRef
  4. Stevenson, DD, Szczeklik, A (2006) Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 118: pp. 773-786 CrossRef
  5. Stevenson, DD, Sanchez-Borges, M, Szczeklik, A (2001) Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 87: pp. 177-180 CrossRef
  6. Hosemann, W (2000) Surgical treatment of nasal polyposis in patients with aspirin intolerance. Review Thorax 55: pp. S87-S90 CrossRef
  7. Lee, RU, Stevenson, DD (2011) Aspirin-Exacerbated Respiratory Disease: Evaluation and Management Allergy. Asthma Immunol Res 3: pp. 3-10 CrossRef
  8. Rozsasi, A, Polzehl, D, Deutschle, T, Smith, E, Wiesmiller, K, Riechelmann, H, Keck, T (2008) Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300?mg aspirin daily. Allergy 63: pp. 1228-1234 CrossRef
  9. Berges-Gimeno, MP, Simon, RA, Stevenson, DD (2003) Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111: pp. 180-186 CrossRef
  10. Steinhubl, SR, Bhatt, DL, Brennan, DM, Montalescot, G, Hankey, GJ, Eikelboom, JW, Berger, PB, Topol, EJ (2009) CHARISMA Investigators, Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 150: pp. 379-386 CrossRef
  11. Miller, B, Mirakian, RM, Gane, S, Larco, J, Al Sannah, A, Darby, YC, Scadding, GK (2013) Nasal lysine aspirin challenge in the diagnosis of aspirin exacerbated respiratory disease. Clin Exp Allergy 43: pp. 874-880 CrossRef
  12. Ragab, S, Parikh, A, Darby, YC, Scadding, GK (2001) An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 31: pp. 1385-1391 CrossRef
  13. Lim, M, Lew-Gor, S, Darby, Y, Brookes, N, Scadding, G, Lund, VJ (2007) The relationship between subjective assessment instruments in chronic rhinosinusitis. Rhinology 45: pp. 144-147
  14. Hox, V, Bobic, S, Callebaux, I, Jorissen, M, Hellings, PW (2010) Nasal obstruction and smell impairment in nasal polyp disease: correlation between objective and subjective parameters. Rhinology 48: pp. 426-432
  15. Holmstrom, M, Scadding, GK, Lund, VJ, Darby, Y (1990) Assessment of nasal obstruction, A comparison between rhinomanometry and nasal inspiratory peak flow. Rhinology 28: pp. 191-196
  16. Kharitonov, S, Alving, K, Barnes, PJ (1997) Exhaled and nasal nitric oxide measurements: recommendations, The European Respiratory Society Task Force. Eur Respir J 10: pp. 1683-1693 CrossRef
  17. McMahon, C, Scadding, GK (1996) Le Nez du Vin–a quic
• 刊物主题：Allergology;
• 出版者：BioMed Central
• ISSN：1939-4551

文摘

Background Aspirin -exacerbated respiratory disease can prove difficult to control. Oral aspirin desensitization is effective, but has adverse effects and may not be cardio-protective at the high doses needed. Objective To examine the effectiveness of aspirin administered in lower doses via the nose. Methods An audit of 121 patients with aspirin exacerbated respiratory disease (AERD), 105 of whom were treated with intranasal lysine aspirin in gradually increasing doses following positive lysine aspirin challenge. Results Treatment was associated with subjective symptomatic improvement or stabilization in 60 of 78 patients at 3?months and 19 of 27 at 12?months. Nasal inspiratory peak flow, olfaction, exhaled and nasal nitric oxide levels were significantly improved (p--.05 for all). Patients with positive skin prick tests and those with later onset (>40?years) AERD improved more than non-atopics and those with early onset AERD. Asthma outcomes over 1?year were assessed by questionnaire in 22 patients on lysine aspirin and in 20 who were positive on challenge but who either refused treatment or took it only briefly (less than or equal to 3?months). There was a significant decrease in emergency visits (p--.0182), hospitalization (p--.0074) and oral steroid use (p--.004) in those on nasal lysine aspirin for a year. Gastrointestinal side effects occurred in 3.8%, lower than those reported for oral aspirin therapy. Conclusions and Clinical Relevance This form of therapy might reduce the need for expensive monoclonal antibodies in AERD patients.